#Canada #Toronto #CDI Labs #PhIP-Seq #antibody

CDI Labs Initiates New Technology Access Program

In a significant move to empower researchers in the field of proteomics, CDI Labs Canada Inc. has unveiled its Technology Access Program designed specifically for custom peptide libraries aimed at serum antibody analysis. This initiative utilizes the innovative method known as phage display immunoprecipitation sequencing (PhIP-Seq), which amalgamates next-generation proteomics with high-throughput DNA sequencing. The objective is to offer scientists unrivaled insights into the complex correlations between antibodies and various diseases, thereby paving the way for advancements in medical research and therapeutic solutions.

Enhancing Research Capabilities

CDI Labs' new offering is a response to the increasing demand for tailored solutions in high-throughput serology, where traditional approaches often fall short. According to Barney Saunders, PhD, CEO of CDI Labs, the company is committed to providing cutting-edge and adaptable services that help researchers uncover crucial insights embedded within serum antibodies. This program enables the epitope-level discovery and analysis of antibodies through specially designed peptide libraries that cater to individual research needs.

This innovation not only enhances the efficiency of antibody profiling but also broadens accessibility to state-of-the-art technology, making it pertinent for a wider scientific audience. The custom PhIP-Seq libraries expand upon the already comprehensive portfolio of serological services offered by CDI Labs, which includes the HuScan® and MouseScan™ services. These existing services analyze diverse samples—such as serum, plasma, and cerebrospinal fluid (CSF)—to detect autoantibodies against a complete reference sequence of human or mouse proteomes within a single-well assay, accompanied by detailed quantitative sequencing data.

The Role of PhIP-Seq in Modern Research

CDI Labs’ introduction of the Technology Access Program aligns with the growing trend in scientific research toward personalized and high-throughput methodologies. PhIP-Seq has revolutionized how researchers analyze the immune response, offering vast multiplexing capabilities that traditional methods simply cannot match. With this program, scientists can now engage in sophisticated profiling of antibodies, which is critical for understanding autoimmune diseases, infections, and other complex health conditions.

CDI Labs Canada, headquartered in Toronto, Ontario, is recognized as a leader in the proteomics domain. The organization is distinguished by its unique offerings that allow customers to decode and characterize molecular interactions across entire proteomes, facilitating a wide range of applications from basic research to clinical deployments.

This advanced program also exemplifies CDI Labs’ focus on advancing research practices by integrating advanced synthetic biology platforms. The company's capacity to generate the largest collection of proteomes globally underscores its commitment to staying at the forefront of proteomics advancements.

About CDI Labs

CDI Laboratories, Inc. is a distinguished contract research organization (CRO) that specializes in proteomics. The company’s pioneering technologies support endeavors in various aspects of research, including autoantibody biomarker discovery, viral exposure profiling, and immunogenic assessments related to therapies. It empowers organizations and researchers by providing indispensable insights that can aid in the development of therapeutics and diagnostics.

For more information about their latest services and technological advancements, CDI Labs invites interested parties to visit their website at cdilabs.com.

Disclaimer: The products and services described here are intended for research purposes only and are not approved for diagnostic procedures. All trademarks mentioned are the property of their respective owners, with VirScan and HuScan being registered trademarks, while MouseScan holds trademark status.

Conclusion

The launch of the Technology Access Program marks an exciting development in the proteomics arena, providing unparalleled resources to advance the field of antibody analysis. As researchers increasingly seek customized solutions to tackle complex scientific questions, CDI Labs stands poised to facilitate groundbreaking discoveries that will contribute to the betterment of human health.